Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation

American Journal of Transplantation

Volumn 11, Issue 9, 2011, Pages 1972-1978

  Levitsky, J ^a   Salomon, D R ^b   Abecassis, M ^a   Langfelder, P ^c   Horvath, S ^c   Friedewald, J ^a   Wang, E ^a,d   Kurian, S M ^b   Mondala, T ^b   Gil, S ^a   McDade, R ^e   Ballard, K ^e   Gallon, L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UCLA Biostatistics   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Rules Based Medicine   (United States)

Author keywords

Biomarkers; calcineurin inhibitor toxicity; kidney injury; nephrotoxicity

Indexed keywords

ALPHA 1 MICROGLOBULIN; APOLIPOPROTEIN C3; BETA 2 MICROGLOBULIN; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 7; CD40 ANTIGEN; CHROMOGRANIN A; CYCLOSPORIN A; CYSTATIN C; FATTY ACID BINDING PROTEIN; INTERLEUKIN 16; INTESTINAL TREFOIL FACTOR; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TACROLIMUS; TREFOIL FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEOMICS; RISK FACTOR;

BIOLOGICAL MARKERS; BLOOD PROTEINS; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROTEOMICS;

EID: 80052273367     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03669.x     Document Type: Article

References (20)

1. Gonwa TA, Mai ML, Melton LB, et al,. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72: 1934-1939. (Pubitemid 34027867)
2. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A,. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: A systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1012-1024.
3. Yu Y, Jin H, Holder D, et al,. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 28: 470-477.
4. Biancofiore G, Pucci L, Cerutti E, et al,. Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl 2006; 12: 285-291. (Pubitemid 43273789)
5. Niemann CU, Walia A, Waldman J, et al,. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl 2009; 15: 1852-1860.
6. Boudville N, Salama M, Jeffrey GP, Ferrari P,. The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. Nephrol Dial Transplant 2009; 24: 2926-2930.
7. Textor SC, Wiesner R, Wilson DJ, et al,. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332-1339. (Pubitemid 23183247)
8. Ko GJ, Grigoryev DN, Linfert D, et al,. Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition. Am J Physiol Renal Physiol 298: F1472-F1483.
9. Dusse LM, Carvalho MG, Cooper AJ, Lwaleed BA,. Plasma factor VII: A potential marker of pre-eclampsia. Thromb Res 127: e15-e19.
10. Alachkar N, Ugarte R, Huang E, et al,. Stem cell factor, interleukin-16, and interleukin-2 receptor alpha are predictive biomarkers for delayed and slow graft function. Transplant Proc 42: 3399-3405.
11. Lajer M, Tarnow I, Michelson AD, et al,. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets 21: 525-532.
12. Vincent C, Dennoroy L, Revillard JP,. Molecular variants of beta 2-microglobulin in renal insufficiency. Biochem J 1994; 298 (Pt 1): 181-187.
13. Laxmanan S, Datta D, Geehan C, Briscoe DM, Pal S,. CD40: A mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol 2005; 16 (9): 2714-2723.
14. Shlipak MG, Fried LF, Stehman-Breen C, Siscovick D, Newman AB,. Chronic renal insufficiency and cardiovascular events in the elderly: Findings from the Cardiovascular Health Study. Am J Geriatr Cardiol 2004; 13: 81-90.
15. Flynn FV, Lapsley M, Sansom PA, Cohen SL,. Urinary excretion of beta 2-glycoprotein-1 (apolipoprotein H) and other markers of tubular malfunction in "non-tubular" renal disease. J Clin Pathol 1992; 45: 561-567.
16. Chan DT, Dogra GK, Irish AB, et al,. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: Potential role of apolipoprotein C-III. J Lipid Res 2009; 50: 2524-2531.
17. Pelsers MM,. Fatty acid-binding protein as marker for renal injury. Scand J Clin Lab Invest Suppl 2008; 241: 73-77. (Pubitemid 351883662)
18. O'Riordan A, Johnston O, McMorrow T, et al,. Identification of Apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques. Proteomics Clin Appl 2008; 2: 1338-1348.
19. Tzur S, Rosset S, Shemer R, et al,. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128: 345-350.
20. Genovese G, Friedman DJ, Ross MD, et al,. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.